May 6, 2009 (FinancialWire) — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (Current Market Cap: US$128.01 Mil.) said it is reducing its staff by half, or around 60 employees, as a part of its restructuring program.

According to Neurocrine, the restructuring is meant to focus the company’s efforts on its clinical programs and pre-clinical development leads.

Kevin C. Gorman, the company’s president and CEO, said that Neurocrine will maintain its efforts on elagolix, an endometriosis drug, move its VMAT2 gene program “into the clinic,” and that Neurocrine would also “focus on the other high value assets.”

San Diego-based Neurocrine Biosciences is a biopharmaceutical company focused on neurological and endocrine diseases and disorders.

The company’s product candidates address markets, including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia, irritable bowel syndrome and other neurological and endocrine related diseases and disorders.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.